Summary by Futu AI
Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd) announced that a private equity fund established by a holding subsidiary/company participated in the formation of the Shenzhen biomedical industry fund, which completed the filing of private equity investment funds on March 12, 2024. The fund was jointly funded by Shenzhen Foshin Shenyao Investment Partnership Enterprise (Limited Partnership), Fosun Pharmaceutical Industry Development (Shenzhen) Co., Ltd., Shanghai Rehab Equity Investment Fund Management Co., Ltd., and other seven investors. The fund manager is Shanghai Rehab Equity Investment Fund Management Co., Ltd., and the custodian is China Construction Bank Co., Ltd. The board of directors of Fosun Pharma guarantees the truthfulness, accuracy, and completeness of the announcement and bears the corresponding legal responsibility. The establishment of the fund aims to invest in the biomedical industry, and it is managed by a holding subsidiary of Fosun Pharma. This development was announced by the board of directors of Fosun Pharma on June 25, 2024.